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Review Article

Current Role of Laser Interstitial Thermal Therapy in the Treatment of
Intracranial Tumors
Abstract

Laser interstitial thermal therapy (LITT) is gaining popularity in the treatment of both primary
and secondary intracranial tumors. The goal of LITT is to deliver thermal energy in a predictable,
controlled, and minimally invasive fashion. It can be particularly valuable in patients with recurrent
tumors who, due to previous radiation or surgery, may have a potentially higher risk of wound
breakdown or infection with repeat craniotomy. Deep‑seated lesions that are often inaccessible
through open approaches (thalamus, hypothalamus, mesial basal temporal lobe, brainstem) may
also be suitable targets. The experience and data published thus far on this modality is limited but
growing. This review highlights the use of LITT as a primary treatment method in a variety of
intracranial tumors, as well as its application as an adjunct to established surgical techniques.
Keywords: Brain metastasis, brain tumor, laser ablation

Introduction
The concept of laser interstitial thermal
therapy (LITT) for tumors has existed since
the late 1970s. Technical limitations of
appropriate laser systems, lack of accurate
targeting of desired treatment areas,
and the inability to monitor the thermal
effects produced were some of the reasons
limiting the widespread application of this
technique. In 1983, Bown et al. reported
the use of a neodymium‑doped yttrium
aluminum garnet (Nd:YAG) laser in an
experimental brain tumor model achieving
focal tissue coagulation.[1] Several animal
studies followed by clinical trials recognize
the viability of LITT in treating intracranial
tumors, and in 1990, Sugiyama et al.
first reported the use of LITT in treating
brain tumors.[2] Multiple subsequent
studies explored its utility in brain tumor
ablation.[3‑10] Despite the availability of
magnetic resonance thermography (MRT),
a lack of sophisticated laser probes with
in‑built cooling systems and unavailability
of intraoperative magnetic resonance
imaging (MRI) prevented this modality
from gaining widespread usage. With
advances in technology, the last decade has
seen a resurgence in interest in the use of
the technique.
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Two systems are currently approved by the
US Food and Drug Administration (FDA)
for intracranial application: Monteris
NeuroBlate
(Monteris,
Plymouth,
Minnesota‑First approved in 2009) and
the Medtronic Visualase (Medtronic,
Minneapolis, Minnesota). The NeuroBlate
uses a CO2 cooled Nd: YAG laser with a
1064‑nm wavelength while the Visualase
uses a saline‑cooled diode laser with a
980‑nm wavelength.[11,12] The two systems
differ slightly in their degree of tissue
penetration with the NeuroBlate system
being able to achieve slightly larger
ablation volumes. Both systems employ a
fiberoptic catheter placed under stereotactic
guidance through which light energy is
delivered to the target tissue in the form of
thermal energy. The thermal energy causes
protein denaturation, melting of membrane
lipids, vessel sclerosis, and coagulation
necrosis, which occurs at 60C, while
apoptosis is triggered between 43C and
60C. Based on the optical characteristics
of the normal brain parenchyma and
pathological tissue, the lesion created can
be conformed to the boundaries of the
target lesion. Following LITT, three zones
can be identified on MRI. The innermost
zone is the zone of coagulation necrosis, the
second (peripheral) zone also has nonviable
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tissue with increased interstitial fluid, and the outermost
zone is the marginal zone consisting of edematous but
viable surrounding brain parenchyma.[13]
The goal of this modality is to deliver thermal energy in a
predictable and controlled fashion. This has been possible
with MRI thermography providing real‑time imaging cues,
which allows optimal heating of the target tissue without
significant char formation or unintended normal tissue
destruction. A small scalp incision and burr hole provide
access to deep‑seated lesions, which would otherwise be
difficult to reach through a traditional open craniotomy.[14,15]

Role in Primary Brain Tumors [Table 1]
Newly diagnosed high‑grade gliomas (HGGs), specifically
the World Health Organization (WHO) Grade IV
gliomas, have a dismal prognosis. Depending on age,
preoperative Karnofsky Performance Scale, and extent
of resection on initial surgery, overall survival (OS) is
best estimated at 12–16 months. Similarly, recurrent
HGGs have a poor prognosis overall, an estimated
39 weeks for anaplastic astrocytomas, and 30 weeks
for grade IV gliomas.[16] Several therapies have been
tested for recurrent HGGs, including repeat craniotomy
for cytoreduction, chemotherapeutic trials of repeat
temozolomide, bevacizumab, gliadel wafer implantation,
and more recently the approval of tumor treating fields.[17]
With open surgery for recurrent lesions, the risk of wound
complications may be higher and access to deep‑seated
lesions may present a challenge. This is where LITT
may have a role in appropriately selected patients.[15]
Han et al. showed that while laser ablation is minimally
invasive (less blood loss, less pain, early resumption of
adjuvant treatment) it is not particularly beneficial when
it comes to larger or amorphous lesions.[18] When such
lesions are present, there is a need for multiple probes
and repositioning, which will add to the duration of the
surgery and the invasiveness of the procedure.
Several of the early reports on the use of LITT were on
patients with recurrent HGG. In 1998, Reimer et al.
presented their experience of four patients with recurrent
high‑grade gliomas who were palliatively treated with
LITT.[10] After LITT, all patients were clinically stable
at 6 months with good local tumor control. In 2002,
Leonardi et al., presented their work on 24 patients (seven
low‑grade gliomas, eleven anaplastic astrocytomas, six
grade IV gliomas) with mean survival times of 34, 30, and
9 months, respectively.[19] Meantime to progression after
LITT for the three histological subgroups were 16 months,
10 months, and 4 months, respectively. In 2005 and 2006,
Schwarzmaier et al. published their initial experience
with a total of eighteen patients with recurrent grade IV
glioma.[11,20] In their initial report, survival times of 16
and 20 months was noted in two patients. In a subsequent
report of sixteen patients, the survival time of 11.2 months
was seen, significantly longer compared with historical

controls. Compared to other treatment combinations, these
were rather promising results for recurrent HGG.
In 2012, Jethwa et al., from the United States (US) and
Carpentier et al., from France reported their experiences
with the Visualase system.[21,22] In the series from the US,
twenty patients were included of which seven had recurrent
or newly diagnosed HGG. One patient in this group had
malignant cerebral edema following the procedure requiring
a decompressive hemicraniectomy. In the series from
France, four patients were included with recurrent grade IV
gliomas, and all of them achieved complete lesional
ablation. The median progression‑free survival (PFS) was
1 month, and the median OS was 10 months.[21,22]
In 2013, Sloan et al. reported their outcomes of ten patients
with recurrent grade IV glioma in a phase 1 safety analysis,
and noted a median OS of 10.5 months.[23] Three patients
had new or worsening neurological deficits after the
procedure, of which two were transient. One of the patients
had a vascular injury resulting in a pseudoaneurysm, which
was subsequently treated by endovascular means.
Similarly, Hawasli et al. reported their initial experience in
2013.[24] It included eleven patients with newly diagnosed or
recurrent HGGs out of the total study population of seventeen
patients. In this patient cohort, progression within the
observation period (0.1–11.2 months) was seen in five of the
eleven patients. Recurrence‑free survival for recurrent HGG
was noted to be 8.4 months, slightly higher than recurrent
tumors treated with bevacizumab. The small patient number,
however, does not allow one to generate any meaningful
conclusion. Two of the glioma patients had postoperative
transient neurological deficit, while one died from meningitis.
Mohammadi et al., in their report from 2014, enrolled
34 patients with HGG who underwent LITT with
the Neuroblate system.[25] This was a retrospective,
nonrandomized study with a heterogeneous patient
population. Sixteen patients with a new diagnosis, and
eighteen patients with recurrent HGG were included.
A 68% 1‑year survival rate and 5.1‑month median PFS
rate was noted. Significant morbidity was associated
with the procedure, with 13 of 34 patients having a
neurological complication. Twenty‑three patients had
recurrences after a median of 7.2 months of follow‑up;
five within the treatment field, twelve at the periphery,
five were outside the enhancing volume but within 2 cm,
and one was remote. Importantly, a higher percentage of
contrast‑enhancing tumor ablation was associated with
increased survival (9.7 vs. 4.6 months, <0.05 cm3 of tumor
remaining). This study signifies that the cytoreductive
effect of hyperthermia can be considered equivalent to
surgical debulking.
In 2016, Leuthardt et al. treated twenty patients with
recurrent HGGs.[26] An interesting aspect of this report was
the testing of the level of brain‑specific enolase as a marker
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Study
Reimer et al.,
1998[9]
Leonardi
et al., 2002[17]
Schwarzmaier
et al., 2005[10]
Schwarzmaier
et al., 2006[18]
Jethwa et al.,
2012[19]

Table 1: Studies on role of laser interstitial thermal therapy in primary brain tumors
Number of
patients
4

24 (7 LGGs, 11
AAs 6 GBMs)
2 (Recurrent
GBMs)
16
20

Reported outcomes/complications

System used

LITT as palliative treatment. All clinically stable at six months with good local
control
Mean survival time with LITT: 34, 30, and 9 months, respectively

Neodym‑YAG
laser
Nd‑YAG laser

Survival time after the diagnosis of recurrence was 16 and 20 months
respectively (four times longer than the natural history of the disease)
Median survival increased to 11.2 months

Nd‑YAG laser

Visualase
system

Carpienter
et al., 2012[20]

4

Complications: One case each of insertion related hemorrhage, diabetes
insipidus and metabolic derangement, significant cerebral edema requiring
decompressive craniectomy, and inaccurate registration missing the target lesion
Median PFS=1 month. Median OS=10 months

Sloan et al.,
2013[21]

10

Complications: One transient supplementary motor area syndrome, one epileptic
seizure, and one CSF leak
Ten patients with recurrent GBM. Median OS=10.5 months

Hawasli et al.,
2013[22]

11 (HGGs)

Mohammadi
et al., 2014[23]

34 (HGG)

Leuthardt
et al., 2016[24]
Thomas et al.,
2016[25]

20 (recurrent
HGGs)
8

Complications: Three patients with new or worsening neurological deficits. One
patient with a vascular injury resulting in a pseudoaneurysm
Eleven patients with newly diagnosed or recurrent HGGs: Five of eleven
patients had progression. PFS for recurrent HGG=8.4 months. Complications:
Two patients had postoperative transient neurological deficit, while one died
from meningitis
Thirty‑four patients with HGG, Median PFS=5.1 months. 68% 1‑year survival
rate
Complications: Seven cases of worsening preoperative neurological deficits,
one case of new seizure, one case of postoperative hyponatremia, one case of
bilateral DVT, and two cases of infection
Two cases of radiological progression seen within 10 weeks of LITT

Nd‑YAG laser

Visualase
system
Neuroblate
system
Neuroblate
system
Neuroblate
system

Neuroblate
system
Visualase and
neuroblate
system

Eight newly diagnosed GBMs: median PFS=2 months, median survival=8
months
Thirteen recurrent GBM: median PFS=5 months, median survival >7 months
79
Comparison between LITT (79 patients) and Craniotomy (1036 patients).
Barnett et al.,
5.7% chance of major complication in LITT compared to 13.9% for traditional
2016[26]
craniotomy
Mohammadi
48 (24 LITT,
Comparison of LITT with biopsy only patients. Median PFS=4.3 months and
Neuroblate
et al., 2019[27]
24 biopsy only)
5.9 months, respectively. Median OS: 14.4 months and 15.8 months respectively
system
Complications: Six cases of worsening neurological deficits, one case of DVT,
and twenty cases of moderate to severe intratumoral bleeding
GBMs – Glioblastoma Multiformes; HGGs – High‑grade gliomas; LITT – Laser interstitial thermal therapy; PFS – Progression‑free
survival; OS – Overall survival; DVT: Deep vein thrombosis, LGGs: Low grade gliomas, AAs: Anaplastic astrocytomas

of blood‑brain‑barrier disruption, postulated to enhance
drug delivery. In this patient cohort, no peri‑procedural
complications were noted. Late clinical and radiological
follow‑up was not recorded, although two cases of
radiological progression were seen within 10 weeks of
LITT. Thomas et al. recently published their series that
included eight patients with newly diagnosed grade IV
glioma and thirteen patients with recurrent disease.[27]
This study is unique as it assessed the molecular status of
the newly diagnosed grade IV group (greater proportion
had IDH wild‑type GBMs). In this group, the median
PFS and median OS was 2 and 8 months, respectively.
Radiographic involution of the tumor was not seen in any
patient. In the thirteen patients with recurrent disease, five
802

had a demonstrable response with concurrent radiographic
shrinkage of the tumor following ablation. Median PFS
was 5 months, and the median OS was >7 months.
In a recent systematic review, open craniotomy for new
or recurrent HGG in eloquent or deep‑seated areas, and
minimally invasive laser ablation technique were assessed
head to head.[28] Eight LITT studies with seventy‑nine
patients and twelve craniotomy studies, including
1,036 patients, were identified by the authors. Meta‑analysis
demonstrated the extent of an ablation of 85.4% ±
10.6% with brain LITT versus extent of resection of
77.0% ± 40% with craniotomy. Analysis of complications
revealed 5.7% (95% confidence interval [CI]: 1.8–11.6)
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chance of major complication in the LITT procedure versus
13.8% (95% CI: 10.3–17.9) for traditional craniotomy. This
study was obviously limited by the low number of reported
patients in the LITT group, making a direct comparison
rather difficult.
In 2018, Mohammadi et al. reported the efficacy of laser
ablation followed by standard chemo/radiotherapy for
newly diagnosed grade IV glioma.[29] They also compared
the results of laser ablation therapy (n = 24) to a matched
cohort of patients who underwent only biopsy (n = 24)
followed by chemo/radiotherapy. Overall, the median
estimate of OS and PFS in the laser ablation cohort was
14.4 and 4.3 months compared to 15.8 and 5.9 months for
biopsy only cohort. They concluded that maximum tumor
coverage by laser ablation followed by chemo/radiotherapy
is an effective treatment modality, particularly for patients
with high‑grade gliomas who are either unsuitable for
aggressive surgery or choose not to undergo standard
resection.

Role in Metastatic Lesions [Table 2]
In the landmark study by Patchell et al., surgical
resection of a single focal metastatic lesion with adjuvant
whole‑brain radiotherapy (WBRT) was shown to reduce
local recurrence rates to 10% after 1 year.[30] This study
was a paradigm shift in the standard of care for brain
metastases. Currently, surgical resection, focal radiosurgery
and/or WBRT, and systemic chemotherapy specific to the
tumor type is utilized.[31] However, for certain deep‑seated
metastatic lesions or recurrent disease, surgery or repeat
radiation may not be an option.
In 2008, Carpentier et al., published their pilot clinical
trial of LITT with real‑time MRI in focal intracranial
metastatic lesions, which were resistant to standard
therapy.[32] As a follow‑up to this in 2011, the same
group reported their outcomes in phase I trial of seven
patients receiving 15 treatments for breast and lung
adenocarcinoma metastases. Tumor size in these patients
did not exceed 30 mm. No major complications were noted
in this series. Mean PFS was noted to be 3.8 ± 1 month.

Study
Carpienter
et al., 2008[32]
Carpienter
et al., 2011[33]
Hawasli et al.,
2013[24]
Ali et al.,
2016[35]

There was a difference between the fully treated subset
and the partial treatment group. Median OS was estimated
to be 17 months.[33] Hawasli et al., in their 2013 report
also included five metastatic lesions.[24] Two patients had
transient postoperative deficits. Out of the five patients,
three had good local disease control, whereas the other
two had central and systemic disease progression. Most
recently, Chaunzwa et al., presented the results of a
multi‑center retrospective study in which thirty patients
with metastatic lesions were included. Good local control
was noted at 6 months, reaching 93%. Twenty‑four lesions
were biopsied, however only five of these revealed tumor
four of which required a salvage craniotomy. The rest were
consistent with radiation necrosis (RN).[34]
Another recent multicenter study by Ali et al., in 2016
showed the use of LITT in postradiosurgery recurrence of
metastatic lesions.[35] Twenty‑six lesions in twenty‑three
patients who recurred after stereotactic radiosurgery (SRS)
were treated with ablation. Nine lesions progressed despite
treatment (35%). All cases of progression occurred in
lesions with <80% ablation, whereas stability was achieved
in those with ≥80% ablation. Five lesions were treated with
a combination of laser ablation followed 1 month later by
adjuvant SRS (5 Gy daily × 5 days). No disease progression
was observed in these patients despite an ablation efficiency
of <80%. This may suggest an augmented effect of laser
ablation with SRS, or simply efficacy of the SRS itself,
which has been shown to be effective up to three or more
times in the same lesion.[36]

Role in Posttreatment Radiation Necrosis
Most treatment regimens for intermediate and high‑grade
brain tumors require some form of radiation therapy as part
of the treatment armamentarium. RN can occur as a result,
and in certain cases, it can be severe enough to cause
local mass effect and significant edema. It can also mimic
tumor progression that may require resection through
craniotomy, or repeat radiation, which may exacerbate the
issue. The incidence of posttreatment RN has been reported
to be as high as 50% with 16–22 Gy treatment dose.

Table 2: Studies on role of laser interstitial thermal therapy in metastatic tumors

Number of patients
4 (6 lesions)

5 (Mets)

Reported outcomes/complications
Gradual and steady decrease in lesion volume with no tumor recurrence
within thermal ablation zones
Mean OS: 17.4+/‑3.5 months. Mean PFS: 3.8+/‑1.0 months. No major
complications noted.
Median OS: 5.8 months. Two patients had transient postoperative deficits

23

Lesions in which <80% ablation was achieved, 35% of these progressed

7 (15 lesions)

Complications: Three patients had transient hemiparesis, one developed
hydrocephalus, and one required emergency hemicraniectomy
Chaunzwa
30
OS: 52.3% at 6 months, 26.1% at 12 months, 21.8% at 18 months, and
et al., 2017[34]
16.3% at 30 months
PFS – Progression‑free survival; OS – Overall survival
Asian Journal of Neurosurgery | Volume 15 | Issue 4 | October-December 2020

System used
Visualase
system
Visualase
system
Neuroblate
system
Visualase and
neuroblate
system
Neuroblate
system
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Few therapeutic options are available for the treatment of
this problem. Steroids temporarily alleviate the situation
but are not a viable long‑term solution. Vitamin E and
pentoxifylline have been tested, and recently a trial of
intra‑arterial bevacizumab has been initiated (LIBERTI,
Dashti et al.).[37,38] LITT has shown to have some promising
effects as well. Laser ablation for RN targets not only
the necrotic mass but also the peri‑necrotic region, which
is the bed of vascular endothelial growth factor (VEGF)
production. RN becomes symptomatic largely due to
perilesional edema. This is driven by VEGF production,
leading to disorganized angiogenesis. The obliteration of
this peri‑necrotic region leads to an effective ablation. In
the first description of this application, Rahmathulla et al.
included a margin of 0.5 cm around the lesion and achieved
good control.[39] Rao et al. in 2014 published their report of
fifteen treatments in fourteen patients for previously treated
metastatic disease, with either symptomatic recurrence or
radiographic recurrence.[40] The lesions were considered to
be either RN or metastatic disease, as no tissue diagnosis
differentiating between the two was obtained before laser
ablation. Good local control was achieved in twelve
patients, with two requiring surgical resection after the
failure of LITT. The median PFS was 37 weeks, and OS
was 57%. The tissue pathology did not reveal any tumor
cells in these two patients, indicating RN. In 2016, Smith
et al., in their series of 25 patients with biopsy‑confirmed
RN (four of whom were later found to have high‑grade
glioma on craniotomy) showed the safety of LITT and
possibly achieving local control of the RN.[41]
In 2018, Ahluwalia et al., published a multicenter
prospective study of LITT ablation in patients with
radiographic progression after stereotactic radiosurgery for
brain metastases.[42] Forty‑two patients were included: 19
with biopsy‑proven RN, twenty with the recurrent tumor,
and three with no diagnosis. Twenty‑seven patients (64%)
had complete data for the 12 weeks follow‑up, while
sixteen patients (38%) had complete data for the full
26 week follow‑up. Of the data available the local PFS
for the group was 74% at 12 weeks and through the last
follow‑up. When comparing the two groups based on
pathology, they found local PFS was statistically different
at 12 weeks (100% for RN vs 54% for tumor; P = 0.016)
but not at the last follow‑up beyond 12 weeks (91% for RN
vs. 62% for tumor; P = 0.166). OS for the whole group
was 86.5% at 12 weeks and 72.2% at 26 weeks. For RN
patients, OS survival was 100% at 12 weeks and 82.1%
at 26 weeks. Despite positive results, the utility of this
technique in improving OS quality of life remains to be
determined definitively.

lesions, laser ablation may hold some value. Ivan et al., in
their series of five patients harboring previously resected
and radiation, now recurrent convexity meningiomas and a
solitary fibrous tumor, showed reasonable local control in
three out of five cases with short term follow up.[43]

Role in Pediatric Brain Tumors
Laser ablation has not been used extensively in
children harboring brain tumors. Tovar‑Spinoza, in
their report from 2016, described their experience
with eleven children harboring twelve lesions.[44,45] The
pathologies included six pilocytic astrocytomas, one
ependymoma, one medulloblastoma, two choroid plexus
xanthogranulomas in one patient, one subependymal giant
cell astrocytoma (SEGA), and one ganglioglioma. Six
patients received LITT as first‑line therapy. Tumor volume
decreased in the first 3 months after ablation and continued
to decrease by the 4–6 month follow‑up. Two patients
experienced postablation complications: transient right
leg weakness in one patient, and transient hemiparesis,
akinetic mutism, and eye movement disorder in the other.
It is important to note that the intraventricular lesion was
safely treated in this group of patients. Similarly, Dadey
et al. also noted safe ablation of SEGAs in two patients in
their report.[46] The first patient had recurrent disease, which
was treated successfully with LITT. In the second patient,
obstructive hydrocephalus was noted with tumor growth,
prior to treatment with LITT. The patient was treated with
robot‑guided LITT and a ventriculostomy for the resolution
of hydrocephalus, resulting in good tumor control on
subsequent imaging.

Other Neurosurgical Applications of Laser
Interstitial Thermal Therapy
Chronic pain
Lesions in the cingulate gyrus have often been used for
pain management in terminally ill cancer patients and in
the management of psychiatric patients. In 2015, Patel
et al. published their experience with MRI guided LITT
in three patients with chronic refractory cancer‑related
pain who underwent bilateral anterior cingulotomy.[47]
These patients had failed multiple medication trials and
interventions. The median preoperative pain severity (PSS)
and pain interference score (PIS) were 7,7 (range: 7.5‑9.3)
and 9.9 (range: 9.7–10.0), respectively. Postoperatively
the median PSS and PIS were 1.6 (range 1.0 2.8) and
2.0 (range 0.3–2.6), respectively. There was a significant
reduction in pain medications requirement for all three
patients in the follow‑up period, and no adverse effects
were encountered in the procedure.

Role in Recurrent Dural Based Lesions

Spinal metastasis

For recurrent meningiomas, standard therapy is re‑operation
or conformal radiotherapy. Chemotherapeutic options have
been tried with limited efficacy. With these recurrent

Metastatic spinal disease is a source of significant morbidity
in cancer patients.[48] An ideal minimally invasive surgical
approach to spinal metastasis would achieve local tumor

804
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control, allow for fast recovery, minimize postoperative
pain and morbidity, and curtail delays in initiating or
interrupting systemic therapies directed to the primary
tumor. In 2015, Tatsui et al., retrospectively reviewed
11 patients at their institute, all with spinal metastasis from
histologies considered to have an unfavorable response to
conventional external beam radiation therapy.[49] All patients
underwent spinal laser interstitial thermal therapy (SLITT)
with the Visualase laser system. The mean preoperative
Visual Analog Scale (VAS) for pain was 6.8, while the
VAS postoperatively at 30 and 60 days was 4.27 and 2.8,
respectively. The mean preoperative VAS was significantly
higher than the VAS 30 days postoperatively (P = 0.035)
and 60 days postoperatively (P = 0.01). Furthermore,
the mean thickness of the epidural tumor decreased
significantly from 8.82 mm (95% CI 7.38–10.25) prior to
treatment to 6.36 mm (95% CI 4.65–8.07) on the 2 months
follow‑up images (P = 0.0001). They concluded that
SLITT can be used as an alternative to separation surgery
in patients without neurological deficits prior to spinal
stereotactic radiosurgery.
Epilepsy surgery
Up to a third of epilepsy patients have seizures refractory
to medical treatment. In patients with well‑localized
drug‑resistant epilepsy (DRE), surgical resection of the
epileptogenic zone (EZ) is highly effective with the overall
quality of life benefits.[50] Magnetic resonance‑guided laser
interstitial thermal therapy (MRgLITT) is an increasingly
popular surgical option for DRE because it provides
minimally invasive access anywhere in the brain with
minimal disruption to overlying white matter and cortex.
Curry et al., retrospectively reviewed the use of MRgLITT
on five pediatric epilepsy patients whose seizures failed
to improve from medical management with at least two
anti‑epileptic drugs.[51] Postoperatively all patients remained
without complications and were seizure‑free at follow‑up
evaluations ranging 2–13 months. These results showed
a significant potential for MRgLITT to offer a minimally
invasive technique for ablation of epileptic foci.
Eloquent region pathologies
Intracranial lesions in functional areas of eloquence
pose a challenge for surgical resection. In 2019, Kuo
et al. presented their series of five pediatric patients
with intracranial lesions in eloquent areas.[52] Clinical
presentations included intractable epilepsy, hemiparesis,
and aphasia by entities, including tumor, dysplasia, and
RN. Postoperatively, all patients improved clinically and
remained stable through follow‑up. Furthermore, in 2020
Easawaran et al., presented the case of an 11‑year‑old boy
with a growing left insular mass determined to be WHO
grade II diffuse astrocytoma.[53] After the initial resection,
the patient underwent laser ablation due to recurrence. At
both 1‑ and 6‑month follow‑up the patient remained stable
and seizure‑free. For intracranial lesions involving the

eloquent cortex, open resection presents as a challenge and
LITT can be used as a potentially effective option.

Discussion
LITT can be a valuable tool in patients harboring recurrent
tumors who have a potentially higher risk of scalp
breakdown or infection with repeat craniotomy due to
previous radiation or surgery. Deep‑seated lesions which
are inaccessible (thalamus, hypothalamus, mesial basal
temporal lobe, brainstem, etc.) may also be suitable targets.
LITT has shown some efficacy as an alternative to open
craniotomy for deep‑seated metastatic lesions and recurrent
gliomas, however, it is yet to be tested in a comparative
large‑scale study. Similarly, for newly diagnosed HGG or
easily accessible metastatic lesions, there is limited evidence
to support its use as a first‑line treatment. Despite the
minimally invasive approach (small skin incision and bone
opening) the hyperthermia created can result in unwanted
side effects, which be mitigated via open craniotomy
approaches.[25] In addition to the above‑mentioned tumor
types, other tumor types which are considered inoperable,
such as bi‑hemispheric corpus callosum gliomas (butterfly
lesions) may be an entity where combined with stereotactic
biopsy for tissue diagnosis, LITT can play a role in
achieving cytoreduction and thus improve the efficacy of
adjuvant therapy. Use of fiber tractography and in certain
cases angiography to better delineate the vascular anatomy
can be helpful in planning targets and minimizing damage
to adjacent white matter tracts and neurovascular structures.
Combination therapy with LITT, followed by craniotomy
through minimally invasive trans tubular or trans‑sulcal
approach, is an intriguing prospect. In the majority of
reports, LITT has been used in isolation, and craniotomy
for the lesion has been necessitated only if there has been
malignant cerebral edema requiring decompression or if
the tumor continues to show mass effect and associated
symptoms requiring resection.[21,34,35] It is also important to
understand that LITT has traditionally been used thus far for
tumors <3 cm diameter and its use in larger tumors has been
limited due to risk to adjacent vessels, white matter tracts,
ventricular system and to prevent the induction of malignant
edema. It does, however, raise the question that if these
risks are all there and craniotomy will be attempted anyway,
why perform laser ablation initially? Combining the two
modalities appears to be similar to the treatment strategy
for arteriovenous malformations and for certain skull base
lesions, where preoperative embolization readily reduces the
arterial inflow, thereby making the surgical resection less
challenging. Laser ablation can be effective in coagulating
the tumor and changing the consistency, which may allow
a complete resection via a minimally invasive trans‑sulcal
tubular approach rather than a larger craniotomy.[54,55] In this
approach, the laser ablation acts as the actual cytoreduction
therapy akin to maximal safe cytoreduction through open
craniotomy, whereas the craniotomy is to reduce the mass
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effect from the ablated tissue in large tumors. Wright et al.
noted that in ten patients treated with LITT and subsequent
craniotomy, the tumor was current jelly‑like and avascular
when accessed using a trans tubular approach, making the
operation much less involved.[55]
Some of the studies mentioned above have shown
significant prolongation of OS and PFS for recurrent
glioma patients, which may be tied in with the genetics
and molecular markers of those tumors. It remains to be
seen whether primary GBM compared to secondary GBM,
with or without certain genetic mutations, would behave
differently in comparison to each other.[56] Similarly,
metastatic lesions of different origins may respond in a
varied fashion to thermal ablation. LITT is a promising tool
but will require extensive testing in a randomized control
trial setting to understand the indications and effectiveness
of this method before it is accepted as a standard of
care. Currently, one trial is underway to assess LITT for
pediatric central nervous system tumors.[57] Results are
expected for another trial that finished recruiting in 2014
for the treatment of metastatic brain tumors.[58]

intracranial tumors. Despite accumulating evidence to
suggest its efficacy and safety, particularly in the treatment
of recurrent or deep‑seated gliomas and metastatic
lesions, open craniotomy techniques remain standard of
care. The prospect of combining LITT with minimally
invasive craniotomy techniques is exciting. Cost may be a
prohibitive factor, especially in developing countries.
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